SCHEMBL285902

SCHEMBL285902

CCCCc1noc(C)c1C=Cc1nc(C)c(C(=O)OC)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
TSHR P16473 2/20 0.35
HPGD P15428 7/20 0.35
NPSR1 Q6W5P4 2/20 0.35
SMN1; SMN2 Q16637 6/20 0.34
RAB9A P51151 5/20 0.34
KDM4E B2RXH2 4/20 0.34
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 6/20 0.34
NPC1 O15118 4/20 0.34
KMT2A Q03164 4/20 0.34
RXFP1 Q9HBX9 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 3/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285901 1.00 POLB (0.42) POLBTSHRHPGDNPSR1SMN1; SMN2
SCHEMBL286203 0.88 ALDH1A1 (0.38) TSHRHPGDSMN1; SMN2RAB9AKDM4E
SCHEMBL2749746 0.88 ALDH1A1 (0.38) TSHRHPGDSMN1; SMN2RAB9AKDM4E
SCHEMBL286202 0.88 ALDH1A1 (0.38) TSHRHPGDSMN1; SMN2RAB9AKDM4E
SCHEMBL285632 0.87 ALDH1A1 (0.35) POLBHPGDNPSR1SMN1; SMN2KDM4E
SCHEMBL285631 0.87 ALDH1A1 (0.35) POLBHPGDNPSR1SMN1; SMN2KDM4E
SCHEMBL285784 0.87 TSHR (0.35) POLBTSHRHPGDNPSR1SMN1; SMN2
SCHEMBL285868 0.87 IKBKB (0.35) LMNATP53GAA
SCHEMBL285869 0.87 IKBKB (0.35) LMNATP53GAA
SCHEMBL285701 0.86 GABRA5 (0.43) POLBKDM4EALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427459-B1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN LA ROCHE (CH) 2016-09-28 EP disclosed
US-8178522-B2 Thiazoles HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127974-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286116-A1 THIAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286116-A1 THIAZOLES GABRA5, GABRA1, GABRA4 POLB 4094/4885TSHR 814/4885HPGD 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.